OliX Pharmaceuticals raises 110.8 billion KRW via 740,367-share third-party allotment at 10% discount; L'Oreal affiliate participation strengthens strategic partnership, offsetting dilution with growth prospects

Issuance of 740,367 common shares at 149,599 KRW per share (10% discount to reference price of 166,221 KRW) to raise approx. 110.8 billion KRW
Proceeds fully allocated to R&D operating expenses (2026-2028)
Allottees: BOLD (L'Oreal affiliate) 70,367 shares, Brookdale Global Opportunity Fund 435,500 shares, Brookdale International Partners 234,500 shares — 1-year lock-up
Dilution of ~3.6% relative to pre-issuance common shares (20,322,483); limited impact given current market cap of 3.55 trillion KRW
L'Oreal affiliate participation signals strategic partnership, enhancing long-term growth and collaboration prospects
[AI Summary]The equity offering secures 110.8 billion KRW for R&D, with strategic investor L'Oreal affiliate participation boosting technology collaboration expectations. The ~3.6% dilution is offset by growth funding and partnership benefits, resulting in a mildly positive impact